Akari Therapeutics raises $5.5M in dilutive private placement with warrants

Filed May 22, 2026 · Period ending May 20, 2026 · ~1 min read

Key Changes

• high

  Company sold 1.47M ADSs at $3.74/unit plus three series of warrants (H, I, J) exercisable at $3.74, creating significant potential dilution if all warrants are exercised by investors.

  Item 1.01 verify on EDGAR →
• high

  Gross proceeds of $5.5M (minus $125K in fees) will fund working capital and general corporate purposes, providing near-term operational runway for the biotech.

  Item 1.01 verify on EDGAR →
• high

  Warrant issuance requires shareholder approval before becoming exercisable; pre-funded warrants exercisable immediately at nominal price, representing near-term dilution.

  Item 1.01 verify on EDGAR →